A promising micro-cap pharmaceutical and chemical company has shown strength, following an 18-month rally and subsequent 18 months of consolidation. It has successfully retested key levels and appears poised for another 15 to 18 months of upward momentum.
For a secure entry point, consider buying above 197 and implementing a trailing stop-loss strategy in line...
